Halozyme Therapeutics, Inc. · NASDAQ:HALO
Posard Matthew L. sold 18,996 Halozyme Therapeutics, Inc. shares (Form 4)
Traded Sep 16, 2026 · Filed Sep 17, 2026
On Sep 16, 2026, Posard Matthew L. (Director) sold 18,996 Halozyme Therapeutics, Inc. shares at an average US$107.74 for US$2.05M under a trading plan, leaving 58,839 shares. Filed Sep 17, 2026 (Form 4).
- Sold
- 18,996 shares
- Price
- US$107.74 average (US$106.13 to US$108.99)
- Value
- US$2.05M
- Holding after
- 58,839 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Common Stock | Sale | 3,100 | US$106.13 | 74,735 | Direct |
| Sep 16, 2026 | Common Stock | Sale | 3,000 | US$106.83 | 71,735 | Direct |
| Sep 16, 2026 | Common Stock | Sale | 8,896 | US$108.04 | 62,839 | Direct |
| Sep 16, 2026 | Common Stock | Sale | 4,000 | US$108.99 | 58,839 | Direct |
Source
Related
- Halozyme Therapeutics, Inc.
- Posard Matthew L.
- Halozyme Therapeutics, Inc. shareholders
- Form 4 · Posard Matthew L. · Oct 2, 2026
- Form 4 · Posard Matthew L. · May 7, 2026
- Form 4 · Torley Helen · Oct 8, 2026
- Form 4 · Daly James M · Oct 2, 2026
- Form 4 · Torley Helen · Sep 11, 2026
- Form 4 · Appelhans Dannielle · Sep 2, 2026
- Form 4 · Torley Helen · Aug 19, 2026